Deals

Betta Pharmaceuticals Acquires Global Rights to SS202 Ultra‑Long‑Acting Monthly Growth Hormone from Gensciences – Deal Valued at Up to RMB 50 Million Plus Royalties
Betta PharmaceuticalsGensciences

Betta Pharmaceuticals Acquires Global Rights to SS202 Ultra‑Long‑Acting Monthly Growth Hormone from Gensciences – Deal Valued at Up to RMB 50 Million Plus Royalties

Betta Pharmaceuticals Co., Ltd. (SHE: 300558) and Hangzhou Gensciences Biopharmaceuticals Co., Ltd. announced a collaboration under which Betta Pharmaceuticals has acquired the global exclusive rights to the ultra‑long‑acting monthly growth…

Astellas Inks Exclusive Option and License Deal for Audax's DAX-044 – Up to USD 1.3 Billion to Back Tumor-Targeted IL-12 Immunotherapy

Astellas Inks Exclusive Option and License Deal for Audax’s DAX-044 – Up to USD 1.3 Billion to Back Tumor-Targeted IL-12 Immunotherapy

Regeneron Extends BARDA Agreement With $270 Million Inmazeb Supply Deal for U.S. Ebola Preparedness Through 2031

Regeneron Extends BARDA Agreement With $270 Million Inmazeb Supply Deal for U.S. Ebola Preparedness Through 2031

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
BiotechFinance

Fosun Pharma to Hike Aitrox Stake to 72.63% for USD 61M

CancerFinance

GluBio Pharma Raises USD 22M in Series A+ Round to Advance TPD Pipeline

CVDFinance

Ribo Life Science Raises USD 40M in Series E1 Round for siRNA Drug Development

BiotechBridGene Biosciences

BridGene Biosciences Completes USD 38.5M Series B Round with China Funds

Show More